ArticleVaccines2021

Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults.

Eve Versage et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.